← Oncology Approval Tracker

FDA DECISION ·

Itovebi + palbociclib + fulvestrant

inavolisib with palbociclib and fulvestrant · Genentech

FDA approvalNew therapyBreast cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with endocrine-resistant, PIK3CA-mutated, HR-positive and HER2-negative locally advanced or metastatic breast cancer after recurrence during or after adjuvant endocrine therapy; use with palbociclib and fulvestrant after FDA-approved testing.

LAMPGEN ANALYSIS

Why it matters

The triplet combines a PI3K-alpha inhibitor with CDK4/6 inhibition and endocrine therapy for a mutation-defined population.

What research teams should watch

Record the adjuvant endocrine timeline and mutation result, and plan baseline and serial glucose checks alongside blood counts.

PRIMARY RECORDS

Sources